drugset
drugset / Trial / NCT04433845

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845 ↗

Phase 2 Unknown 15 enrolled Sheppard Pratt Health System COMPASS Pathways · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.

Timeline

Start
2021-03-01
Primary completion
2023-01-15
Completion
2023-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg —

Indications

No indication recorded.